Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases
Study Met All Primary and Secondary Endpoints PL-8177 is a Melanocortin Receptor 1 Agonist Apr 04, 2019, 07:30 ET CRANBURY, N.J., April 4, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced positive …